Oculis Holding AG (NASDAQ:OCS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $38.3333.

A number of brokerages have commented on OCS. Stifel Nicolaus reduced their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Robert W. Baird lowered their price objective on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a report on Monday, June 1st. Needham & Company LLC cut their price objective on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Guggenheim reduced their target price on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OCS. Bank of America Corp DE lifted its stake in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares during the period. Aventura Private Wealth LLC purchased a new stake in Oculis during the 4th quarter valued at about $80,000. Geode Capital Management LLC grew its position in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Koshinski Asset Management Inc. bought a new position in Oculis during the 1st quarter worth approximately $238,000. 22.30% of the stock is owned by institutional investors.

Oculis Price Performance

OCS opened at $13.70 on Friday. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $794.33 million, a P/E ratio of -6.43 and a beta of 0.44. The stock has a 50-day moving average price of $19.45 and a 200-day moving average price of $23.70. Oculis has a 12-month low of $10.52 and a 12-month high of $34.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. Equities analysts predict that Oculis will post -2.27 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.